CHINA – Innovac Therapeutics, a Boston, MA-, Shanghai and Hangzhou, China-based mRNA therapeutics company, raised $18M in Series Pre-A funding.
The round saw participation from Elikon Venture, Vision Plus Capital, Yunion Healthcare Ventures, TG Sino-Dragon Fund and other industry and private individuals. Upon closing its Series Pre-A financing, Innovac also announced the appointments of David Bernstein, MD, Shan Lu, MD, PhD, and Elaine Mardis, PhD to its scientific advisory board (SAB).The company intends to use the funds to further develop its technology platform and manufacturing capability to advance its lead programs to clinical stage.Founded in 2022 by CEO Michael Zhang, CTO Hang Yuan, PhD, Chief Scientific Officer, and Nicholas Valiante, Innovac Therapeutics is a biotechnology company dedicated to developing vaccines and therapeutics for patients with unmet medical needs using its proprietary mRNA technology platforms and manufacturing capabilities.04/09/2023
